- Aphria Inc. President, Jakob Ripshtein, is proposed to replace Mr Battersby as Non-Executive Director (pending ODC approval)
- The proposed appointment of Mr Ripshtein further enhances Althea’s global partnership with leading Canadian cannabis producer, Aphria Inc.
- Gregg Battersby has stepped down from his Non- Executive Director role
Thursday 7 March 2019: Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) (“Althea” or ”the Company”) wishes to advise that Gregg Battersby has stepped down from his Non-Executive Director role and that Jakob Ripshtein, President of Aphria Inc (TSX: APHA and NYSE: APHA) (“Aphria”), is proposed to be appointed as a Non-Executive Director of the Company.
To read the ASX Announcement, please click here
To read the Investor Presentation, please click here
About Althea Group Holdings Limited (ASX:AGH)
Althea is a patient-focused medicinal cannabis company that has all the required licenses and permits to import, cultivate, produce and supply medicinal cannabis in Australia. Through a strategic partnership with cornerstone investor Aphria, one of the largest cannabis companies listed in North America, Althea has become a leading supplier of medicinal cannabis in the Australian market.
Althea’s focus on patient care underpins its business strategy. To this end, Althea has developed a mobile application and web-based platform to educate healthcare professionals on the benefits of medicinal cannabis and assist them in navigating the regulatory landscape. Althea is progressing towards its own production facility and is in the process of expanding its product portfolio, patient numbers, and global footprint. | | |
